Susan Abushakra - Concepedia

Author

Susan Abushakra

Framingham State University

Also Known As

S. Abu-Shakra, S. Abushakra, Susan Abu-Shakra, Susan Abu-shakra, Susan Abushakra, Susan Abu‐Shakra, Susan R. Abushakra

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Framingham State University University of Rochester Sunesis (United States)Lou Ruvo Brain Institute Cleveland Clinic

About

Susan Abushakra is an author at Framingham State University specializing in neurology, alzheimer's disease, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	225
2	Health Sciences	2	2	62
3	Social Sciences	2	2	31
4	Public Health	1	1	16
5	Geriatrics	1	1	16

Susan Abushakra

Publications

991

Citations

H-Index

Page 1

	Year	Citations
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease Stephen Salloway, Reisa A. Sperling, Ron Keren, Neurology	2011	252
Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease John A. Hey, Yongxin Yu, Mark Versavel, Clinical Pharmacokinetics	2017	123
Efficacy and Tolerability of Oral Zolmitriptan in Menstrually Associated Migraine: A Randomized, Prospective, Parallel‐Group, Double‐blind, Placebo‐Controlled Study Elizabeth Loder, Stephen D. Silberstein, Susan Abushakra, Headache The Journal of Head and Face Pain	2004	82
Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain John A. Hey, Petr Kočiš, Jakub Hort, CNS Drugs	2018	70
CLINICAL EFFECTS OF TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER’S DISEASE SUGGEST DISEASE MODIFICATION POTENTIAL Susan Abushakra, Anton P. Porsteinsson, Philip Scheltens, The Journal of Prevention of Alzheimer s Disease Neurodegenerative DiseasesAlzheimer's DiseaseMedicineDegenerative PathologyNeurology	2017	69
CLINICAL BENEFITS OF TRAMIPROSATE IN ALZHEIMER’S DISEASE ARE ASSOCIATED WITH HIGHER NUMBER OF APOE4 ALLELES: THE “APOE4 GENE-DOSE EFFECT” Susan Abushakra, Anton P. Porsteinsson, B. Vellas, The Journal of Prevention of Alzheimer s Disease Neurodegenerative DiseasesAlzheimer's DiseaseMedicineDegenerative PathologyNeurology	2016	63
Alzheimer's disease therapeutic trials: EU/US task force report on recruitment, retention, and methodology Bruno Vellas, Harald Hampel, M.-E. Rougé-Bugat, The journal of nutrition health & aging Neurodegenerative DiseasesAlzheimer's DiseaseDementiaPatient RecruitmentClinical Trials	2012	46
Safety and Efficacy of EB-001, a Novel Type E Botulinum Toxin, in Subjects with Glabellar Frown Lines: Results of a Phase 2, Randomized, Placebo-Controlled, Ascending-Dose Study Steve Yoelin, Sunil Dhawan, Domenico Vitarella, Plastic & Reconstructive Surgery	2018	45
Pain-free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double-blind placebo-controlled trial Elizabeth Loder, Frederick G. Freitag, James U. Adelman, Current Medical Research and Opinion	2005	41
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral ELND005 (<i>scyllo</i>-Inositol) in Young Adults with Down Syndrome without Dementia Michael S. Rafii, Brian G. Skotko, Mary Ellen McDonough, Journal of Alzheimer s Disease	2017	37

Page 1